Suppr超能文献

[幽门螺杆菌alpA基因在乳酸乳球菌中的表达及其免疫原性分析]

[Expression of helicobacter pylori alpA gene in lactococcus lactis and its immunogenicity analysis].

作者信息

Sun Zhen-lu, Bi Yan-wei, Bai Cai-ming, Gao Dan-dan, Li Zhi-hua, Dai Zong-xiang, Li Jian-feng, Xu Wei-ming

机构信息

Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China.

出版信息

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2010 Mar;26(3):203-6.

Abstract

AIM

To express Helicobacter pylori (Hp) alpA gene in a live delivery vehicle of lactococcus lactis (L. lactis) and assay the efficacy of the L. lactis-alpA oral vaccine in recipient mice.

METHODS

The alpA gene of Hp was amplified by PCR and cloned into the prokaryotic expression vector pNICE: sec. The recombinant vector pNICE: sec-alpA was transformed into Lactococcus lactis strain NZ9000. Then the engineered strain was induced to express recombinant alpA as shown by SDS-PAGE and Western blot. Female ICR mice (CV Grade) were randomly divided into 4 groups and administrated orally with PBS, L. lactis pNICE: sec, L. lactis pNICE: sec-alpA, and the inactivated Hp, respectively. After immunized seven times, the mice were detected for their alpA-specific IgG and IgA.

RESULTS

The alpA gene was obtained and successfully cloned into the vector pNICE: sec. The recombinant alpA protein (56,000) was accumulated in L. lactis after the induction of the nisin, accounting for 9.6% of the total bacterial protein. Western bolt confirmed that the alpA protein could be recognized specifically by the anti-Hp serum. The titer of anti-alpA IgG in the pNICE: sec-alpA group, comparable to that in the inactivated Hp group, was higher than that in the pNICE: sec group. The titer of anti-alpA IgA in the pNICE: sec-alpA group was higher than all other groups (P<0.05).

CONCLUSION

The oral administration of the engineered alpA-expressing L. lactis induced protective immunity against Hp. Our study provides a certain experimental basis for the use of L. lactis as an antigen-delivering vehicle for the development of Hp oral vaccines.

摘要

目的

在乳酸乳球菌的活载体中表达幽门螺杆菌(Hp)alpA基因,并检测乳酸乳球菌-alpA口服疫苗在受体小鼠中的疗效。

方法

通过PCR扩增Hp的alpA基因,并将其克隆到原核表达载体pNICE:sec中。将重组载体pNICE:sec-alpA转化到乳酸乳球菌NZ9000菌株中。然后诱导工程菌株表达重组alpA,SDS-PAGE和Western印迹显示表达成功。将雌性ICR小鼠(普通级)随机分为4组,分别口服给予PBS、乳酸乳球菌pNICE:sec、乳酸乳球菌pNICE:sec-alpA和灭活的Hp。免疫7次后,检测小鼠的alpA特异性IgG和IgA。

结果

获得alpA基因并成功克隆到载体pNICE:sec中。经乳链菌肽诱导后,重组alpA蛋白(56,000)在乳酸乳球菌中积累,占细菌总蛋白的9.6%。Western印迹证实alpA蛋白能被抗Hp血清特异性识别。pNICE:sec-alpA组抗alpA IgG的滴度与灭活Hp组相当,高于pNICE:sec组。pNICE:sec-alpA组抗alpA IgA的滴度高于其他所有组(P<0.05)。

结论

口服表达alpA的工程化乳酸乳球菌可诱导针对Hp的保护性免疫。我们的研究为将乳酸乳球菌用作抗原递送载体开发Hp口服疫苗提供了一定的实验依据。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验